Posters
Presenting Author Academic/Professional Position
Medical Student
Academic Level (Author 1)
Medical Student
Academic Level (Author 2)
Medical Student
Academic Level (Author 3)
Faculty
Discipline/Specialty (Author 3)
Medical Education
Presentation Type
Poster
Discipline Track
Biomedical Science
Abstract Type
Research/Clinical
Abstract
The property of niclosamide to inhibit multiple cancer-related pathways has made it a promising candidate for the treatment of various cancers. However, poor bioavailability and solubility have significantly restricted its clinical application. This literature review explores various strategies that enhance the bioavailability and efficacy of Niclosamide through the development of Niclosamide derivatives and the utilization of drug delivery systems. We also briefly discuss Niclosamide’s suspected mechanisms of action in several cancer related pathways. Derivatives such as Niclosamide Ethanolamine (NEN) and Niclosamide Piperazine (NPP) have demonstrated improved pharmacokinetic properties, including increased solubility and bioavailability, without compromising anticancer activity. Importantly, these formulations have demonstrated increased anti-tumor activity and reduced systemic toxicity in preclinical studies. These compounds serve as a proof-of-concept regarding the possibility of synthesizing, and eventually incorporating Niclosamide derivatives for their use in certain cancer treatment regiments if clinical trials deem safe and effective. Niclosamide derivatives and utilization of novel vehicles for drug delivery may reduce the side-effect burden associated with unmodified Niclosamide. Ultimately, there is a need for researchers to synthesize, evaluate, and improve upon Niclosamide derivatives, while experimenting with the employment of nanoformulations as a vehicle for drug administration. Researchers should approach the problem with the aim of improving drug-target accuracy, reducing Niclosamide’s side effect profile, and increasing the drugs efficacy as an anti-neoplastic agent.
Recommended Citation
Wiggins, Russell; Woo, Jihoo; and Mito, Shizue, "Improving Niclosamide's Effectiveness in Cancer Therapy: Advances in Drug Modification and Delivery" (2025). Research Symposium. 140.
https://scholarworks.utrgv.edu/somrs/2025/posters/140
Included in
Improving Niclosamide's Effectiveness in Cancer Therapy: Advances in Drug Modification and Delivery
The property of niclosamide to inhibit multiple cancer-related pathways has made it a promising candidate for the treatment of various cancers. However, poor bioavailability and solubility have significantly restricted its clinical application. This literature review explores various strategies that enhance the bioavailability and efficacy of Niclosamide through the development of Niclosamide derivatives and the utilization of drug delivery systems. We also briefly discuss Niclosamide’s suspected mechanisms of action in several cancer related pathways. Derivatives such as Niclosamide Ethanolamine (NEN) and Niclosamide Piperazine (NPP) have demonstrated improved pharmacokinetic properties, including increased solubility and bioavailability, without compromising anticancer activity. Importantly, these formulations have demonstrated increased anti-tumor activity and reduced systemic toxicity in preclinical studies. These compounds serve as a proof-of-concept regarding the possibility of synthesizing, and eventually incorporating Niclosamide derivatives for their use in certain cancer treatment regiments if clinical trials deem safe and effective. Niclosamide derivatives and utilization of novel vehicles for drug delivery may reduce the side-effect burden associated with unmodified Niclosamide. Ultimately, there is a need for researchers to synthesize, evaluate, and improve upon Niclosamide derivatives, while experimenting with the employment of nanoformulations as a vehicle for drug administration. Researchers should approach the problem with the aim of improving drug-target accuracy, reducing Niclosamide’s side effect profile, and increasing the drugs efficacy as an anti-neoplastic agent.
